Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Cosmetics

  • Print
  • Share
  • E-mail
-

BSE and Cosmetics: FDA Risk Assessment and Management Perspectives - Slide 39. BSE Risk Assessment-1

December 7, 2006

First  |  ← Previous  |  Slide 39 of 45  |  Next →  |  Last  |  Index

Slide 39. BSE Risk Assessment-1 - See text below

BSE Risk Assessment-1

  • Hazard Characterization
    • asymptomatic lag period (6 mo. - 4 yr.)
    • Associative PrPc → PrPres conversion in CNS tissue (exponential concentration increase)
    • Dose/Response experimental infectivity in cattle
    • Species Barrier in Humans of 101-104 needed to cause illness compared with cattle
-
-